2024-10-09T17:35:52+08:002023-08-02|
聯絡信息
教學
Education
PhD University of Macau, China, 2020
Msc Guangdong Pharmaceutical University, China, 2014
Bsc Huazhong Agricultural University, China, 2011
Position
12/2022 – Present Research Assistant Professor, Faculty of Health Sciences, University of Macau
01/2021 – 01/2023 UM Macao Postdoctoral Fellowship, Faculty of Health Sciences, University of Macau
Research Interests
  1. Multi-drug resistance in the cancer, mechanisms and treatment strategy,
  2. Protein homeostasis,
  3. Anticancer drug and mitochondrial damage
Representative Publications
  1. Fangyuan Shao, Xueying Lyu, Kai Miao, Lisi Xie, Haitao Wang, Hao Xiao, Qiang Chen, Renbo Ding, Ping Chen, Fuqiang Xing, Xu Zhang, Guang-Hui Luo, Wenli Zhu, Gregory Cheng, Ng Wai Lon, Scott E. Martin, Guanyu Wang, Guokai Chen, Yunlu Dai, Chu-Xia Deng, Enhanced protein damage clearance induces broad drug resistance in multi-type of cancers revealed by an evolution drug resistant model and genome-wide siRNA screening, Advanced Science (2020).
  2.  S. Chen, F.Y. Shao, J.M. Zeng, S. Guo, L.J. Wang, H. Sun, J.H. Lei, X.Y. Lyu, S. Gao, Q. Chen, K. Miao, X.L. Xu, C.X. Deng, Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling, Science Advances, 9 (2023).
  3.  H.T. Wang, S. Guo, S.J. Kim, F.Y. Shao, J.W.K. Ho, K.U. Wong, Z.Q. Miao, D.P. Hao, M. Zhao, J. Xu, J.M. Zeng, K.H. Wong, L.J. Di, A.H.H. Wong, X.L. Xu, C.X. Deng, Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel, Theranostics, 11 (2021) 2442-2459.
  4.  B. Li, H. Chen, S.H. Yang, F. Chen, L.L. Xu, Y. Li, M.Z. Li, C.M. Zhu, F.Y. Shao, X.H. Zhang, C.X. Deng, L.L. Zeng, Y.L. He, C.H. Zhang, Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers, Molecular Cancer, 22 (2023).
  5.  K. Miao, J.H.P. Lei, M.V. Valecha, A.P. Zhang, J. Xu, L.J. Wang, X.Y. Lyu, S. Chen, Z.Q. Miao, X. Zhang, S.M. Su, F.Y. Shao, B.K. Rajendran, J.L. Bao, J.M. Zeng, H. Sun, P. Chen, K.L. Tan, Q. Chen, K.H. Wong, X.L. Xu, C.X. Deng, NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation, Nature Communications, 11 (2020).
  6.  F. Shao, H. Sun, C.X. Deng, Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype, Oncotarget, 8 (2017) 73329-73344.
  7.  F.Y. Shao, S. Wang, H.Y. Li, W.B. Chen, G.C. Wang, D.L. Ma, N.S. Wong, H. Xiao, Q.Y. Liu, G.X. Zhou, Y.L. Li, M.M. Li, Y.F. Wang, Z. Liu, EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells, Oncotarget, 7 (2016) 6790-6808.
  8.  H. Xiao, F. Shao, M. Wu, W. Ren, X. Xiong, B. Tan, Y. Yin, The application of antimicrobial peptides as growth and health promoters for swine, Journal of Animal Science and Biotechnology, 6 (2015) 19.
  9.  F.Y. Shao, Z.Y. Du, D.L. Ma, W.B. Chen, W.Y. Fu, B.B. Ruan, W. Rui, J.X. Zhang, S. Wang, N.S. Wong, H. Xiao, M.M. Li, X. Liu, Q.Y. Liu, X.D. Zhou, H.Z. Yan, Y.F. Wang, C.Y. Chen, Z. Liu, H.Y. Chen, B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy, Oncotarget, 6 (2015) 30939-30956.
  10.  R. Wang*, F. Shao*, Z. Liu, J. Zhang, S. Wang, J. Liu, H. Liu, H. Chen, K. Liu, M. Xia, Y. Wang, The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-kappaB and disruption of mitochondria-dependent pathways, Chemico-Biological Interactions, 205 (2013) 1-10. (*, equal contribution)
  11.  H. Zheng, F. Shao, S. Martin, X. Xu, C.X. Deng, WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance, Scientific Reports, 7 (2017) 43517.
  12.  H. Xiao, M. Wu, F. Shao, G. Guan, B. Huang, B. Tan, Y. Yin, N-Acetyl-L-cysteine Protects the Enterocyte against Oxidative Damage by Modulation of Mitochondrial Function, Mediators of Inflammation, 2016 (2016) 8364279.
  13.  X. Xu, E. Chen, L. Mo, L. Zhang, F. Shao, K. Miao, J. Liu, S.M. Su, M. Valecha, U.I. Chan, H. Zheng, M. Chen, W. Chen, Q. Chen, H. Fu, M.I. Aladjem, Y. He, C.X. Deng, BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy, Human Molecular Genetics, 28 (2019) 842-857.
  14.  H. Li, M. Li, G. Wang, F. Shao, W. Chen, C. Xia, S. Wang, Y. Li, G. Zhou, Z. Liu, EM23, A Natural Sesquiterpene Lactone from Elephantopus mollis, Induces Apoptosis in Human Myeloid Leukemia Cells through Thioredoxin- and Reactive Oxygen Species-Mediated Signaling Pathways, Frontiers in Pharmacology, 7 (2016) 77.
Research Grants
10/2022 – 09/2025 Department of Science and Technology of Guangdong Province (GDSTC) (2022A1515110671)
Mechanism study of bortezomib to overcome multi-drug resistance in the breast cancer.
06/2023 – 01/2024 Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau (SP2023-00001-FSCPO)
Identification of mitochondrial protein damage response genes to overcome multidrug resistance
01/2023 – 12/2024 Seventh Affiliated Hospital of Sun Yat-sen University, Open Fund of Guangdong Provincial Key Laboratory of Digestive Cancer Research (GPKLDCR202207M)
Mechanism study of drug induced protein damage in the digestive system malignancy for clinical usage of the proteasome activity detection kit
Patents
  1. 邓初夏, 邵方元, 彭宗根,李虎,一种缓冲液、试剂盒和蛋白酶体检测方法,中国专利,发明专利, 202211119256.5,申请日:2022-08-27
  2.  邓初夏, 邵方元, 卡非佐米在制备治疗抗药肿瘤的药物中的新的应用,中国专利,发明专利, 202011126326.0,申请日:2020-11-12
  3.  邓初夏, 邵方元, NEW APPLICATION OF CARFILZOMIB IN A PREPARATION OF DRUGS FOR A TREATMENT OF DRUG-RESISTANT TUMORS,国外专利,发明专利,63112168,申请日:2020-11-12